Amphastar Pharmaceuticals (NASDAQ:AMPH) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their hold rating on shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note released on Friday morning, MarketBeat.com reports.

Other analysts have also recently issued research reports about the company. Wells Fargo & Company reduced their price target on Amphastar Pharmaceuticals from $34.00 to $30.00 and set an “overweight” rating for the company in a research report on Friday, February 27th. Barclays lowered their price objective on Amphastar Pharmaceuticals from $30.00 to $23.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 8th. Weiss Ratings lowered shares of Amphastar Pharmaceuticals from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 10th. Finally, Jefferies Financial Group restated a “hold” rating and set a $22.00 target price (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $27.43.

Amphastar Pharmaceuticals Trading Down 20.9%

Shares of AMPH stock opened at $19.00 on Friday. Amphastar Pharmaceuticals has a 1 year low of $17.03 and a 1 year high of $31.26. The firm has a fifty day moving average price of $20.80 and a 200-day moving average price of $24.57. The company has a debt-to-equity ratio of 0.77, a current ratio of 4.02 and a quick ratio of 2.90. The company has a market cap of $846.07 million, a price-to-earnings ratio of 11.45, a PEG ratio of 1.94 and a beta of 0.97.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, May 7th. The company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.28). The company had revenue of $171.17 million during the quarter, compared to the consensus estimate of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.11% and a net margin of 11.00%. As a group, equities analysts predict that Amphastar Pharmaceuticals will post 2.93 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its position in shares of Amphastar Pharmaceuticals by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company’s stock valued at $39,726,000 after buying an additional 228,262 shares during the last quarter. Bessemer Group Inc. grew its stake in Amphastar Pharmaceuticals by 1.0% during the first quarter. Bessemer Group Inc. now owns 122,046 shares of the company’s stock valued at $2,391,000 after acquiring an additional 1,156 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $753,000. Louisiana State Employees Retirement System bought a new stake in Amphastar Pharmaceuticals in the 1st quarter valued at $308,000. Finally, Pacer Advisors Inc. increased its holdings in Amphastar Pharmaceuticals by 2,864.4% in the 4th quarter. Pacer Advisors Inc. now owns 177,744 shares of the company’s stock valued at $4,760,000 after acquiring an additional 171,748 shares during the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals News Roundup

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Negative Sentiment: Amphastar reported adjusted earnings of $0.42 per share on revenue of $171.2 million, missing analyst estimates of about $0.70 EPS and $173.5 million in sales, which is the main reason the stock is moving lower. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
• Negative Sentiment: The company’s GAAP net income was $6.4 million, or $0.14 per share, highlighting weaker bottom-line performance than the adjusted figures suggest. Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026
• Neutral Sentiment: Needham & Company reaffirmed its hold rating, suggesting analysts are cautious but not turning more bearish after the results.
• Neutral Sentiment: Management also said BAQSIMI revenue is expected to be flat to up low-single-digits, with a 3% list price increase, offering some stability in a key product line. Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.